These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15025797)

  • 1. Cyclooxygenase-2 expression in right- and left-sided colon cancer: a rationale for optimization of cyclooxygenase-2 inhibitor therapy.
    Nasir A; Kaiser HE; Boulware D; Hakam A; Zhao H; Yeatman T; Barthel J; Coppola D
    Clin Colorectal Cancer; 2004 Feb; 3(4):243-7. PubMed ID: 15025797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms.
    Nasir A; Fernandez PM; Chughtai OR; Kaiser HE
    In Vivo; 2002; 16(6):501-9. PubMed ID: 12494894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between COX-2 and APC expression in left versus right-sided human colon cancer.
    Nasir A; Lopez A; Boulware D; Malafa M; Coppola D
    Anticancer Res; 2011 Jun; 31(6):2191-5. PubMed ID: 21737640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
    Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
    Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.
    Okajima E; Uemura H; Ohnishi S; Tanaka M; Ohta M; Tani M; Fujimoto K; Ozono S; Okajima E; Hirao Y
    Aktuelle Urol; 2003 Jul; 34(4):256-8. PubMed ID: 14566678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis of colorectal cancer - role of gastrin and cyclooxygenase-2.
    Hartwich J; Konturek SJ; Pierzchalski P; Zuchowicz M; Konturek PC; Bielański W; Marlicz K; Starzyńska T; Ławniczak M
    Med Sci Monit; 2001; 7(6):1171-81. PubMed ID: 11687726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
    Ferrandina G; Ranelletti FO; Legge F; Lauriola L; Salutari V; Gessi M; Testa AC; Werner U; Navarra P; Tringali G; Battaglia A; Scambia G
    Clin Cancer Res; 2003 Oct; 9(12):4324-31. PubMed ID: 14555502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):306-16. PubMed ID: 11769882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
    Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
    FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [COX-2 inhibitor and colon cancer].
    Tsujii M
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1799-805. PubMed ID: 11729471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.
    Sheng H; Shao J; Morrow JD; Beauchamp RD; DuBois RN
    Cancer Res; 1998 Jan; 58(2):362-6. PubMed ID: 9443418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: clinical and in vitro studies.
    Chen WC; McBride WH; Chen SM; Lee KF; Hwang TZ; Jung SM; Shau H; Liao SK; Hong JH; Chen MF
    Head Neck; 2005 Jun; 27(6):503-12. PubMed ID: 15772955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
    Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
    Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas.
    Adegboyega PA; Ololade O; Saada J; Mifflin R; Di Mari JF; Powell DW
    Clin Cancer Res; 2004 Sep; 10(17):5870-9. PubMed ID: 15355919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) expression in human pituitary macroadenomas.
    Bloomer CW; Kenyon L; Hammond E; Hyslop T; Andrews DW; Curran WJ; Dicker AP
    Am J Clin Oncol; 2003 Aug; 26(4):S75-80. PubMed ID: 12902861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
    Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between COX-2 expression and clinicopathological features of colorectal cancers.
    Zhan J; Liu JP; Zhu ZH; Yao HR; Chen CY
    Chin Med J (Engl); 2004 Aug; 117(8):1151-4. PubMed ID: 15361286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COX-2: a molecular target for colorectal cancer prevention.
    Brown JR; DuBois RN
    J Clin Oncol; 2005 Apr; 23(12):2840-55. PubMed ID: 15837998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
    Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
    Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
    Spieth K; Kaufmann R; Gille J
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):377-82. PubMed ID: 12879280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.